Search research articles
Contact Us
Filters
Showing results (451-460 of 472) with videos related to
Page
of 48
Sort By:
Blood Cancer Journal
|
August 26, 2017
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
J Hillengass, L A Moulopoulos, S Delorme, et al.
Bone Marrow Transplantation
|
June 8, 2006
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma
N W C J van de Donk, N Kröger, U Hegenbart, et al.
Journal of Internal Medicine
|
February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S Bringhen, A Milan, M D'Agostino, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Leukemia
|
January 18, 2008
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
J F San-Miguel, P G Richardson, P Sonneveld, et al.
Leukemia
|
December 21, 2011
Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium
A Martino, D Campa, G Buda, et al.
Leukemia
|
December 17, 2015
Genetic factors influencing the risk of multiple myeloma bone disease
D C Johnson, N Weinhold, J Mitchell, et al.
Bone Marrow Transplantation
|
January 27, 2015
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
S Iacobelli, L C de Wreede, S Schönland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer
David R Spigel, Thomas J Ervin, Rodryg A Ramlau, et al.
Page
of 48
Search research articles
Search
Showing results (451-460 of 472) with videos related to
Sort By:
Page
of 48
Blood Cancer Journal
|
August 26, 2017
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
J Hillengass, L A Moulopoulos, S Delorme, et al.
Bone Marrow Transplantation
|
June 8, 2006
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma
N W C J van de Donk, N Kröger, U Hegenbart, et al.
Journal of Internal Medicine
|
February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S Bringhen, A Milan, M D'Agostino, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Leukemia
|
January 18, 2008
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
J F San-Miguel, P G Richardson, P Sonneveld, et al.
Leukemia
|
December 21, 2011
Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium
A Martino, D Campa, G Buda, et al.
Leukemia
|
December 17, 2015
Genetic factors influencing the risk of multiple myeloma bone disease
D C Johnson, N Weinhold, J Mitchell, et al.
Bone Marrow Transplantation
|
January 27, 2015
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
S Iacobelli, L C de Wreede, S Schönland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer
David R Spigel, Thomas J Ervin, Rodryg A Ramlau, et al.
Page
of 48